Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zydus Launches First Kadcyla Biosimilar in India At Sharp Discount

Another In Works From Hetero

Executive Summary

Zydus Cadila’s launch of the world’s first biosimilar to Roche’s breast cancer drug Kadcyla in India at an 80% discount to the original's listed price is expected to improve access, and follows its pioneering launch of an adalimumab biosimilar and a NASH therapy.

You may also be interested in...



Zydus Cadila Strengthens Pipeline With 35 FDA Approvals

India’s Zydus Cadila is working on strengthening its pipeline with 35 product approvals from the FDA over the course of its most recent financial year. The company also filed for 22 new ANDAs during FY2021. And ahead of recently launching the world’s first biosimilar to Roche’s Kadcyla (trastuzumab emtansine) in India, the company reported significant growth in its domestic business. 

AZ Bets Big On ADCs As It Inks Second, $6bn Deal With Daiichi

Following their original March 2019 tie-up for an oncology antibody-drug conjugate, Daiichi Sankyo and AstraZeneca have entered into a new global deal worth up to $6bn for a second novel asset from the Japanese firm, with potential in breast, lung and other cancers.

Stockwatch: Bullishness Or Belligerence At Roche And Biogen?

After only two weeks of the first-quarter 2020 earnings season for biopharmaceutical companies, the tempo of the announcements seems already to have been defined. Unless companies are exposed to, on the one hand, medical devices, or on the other, consumer health or diagnostics, the impact of the coronavirus pandemic on pure play biopharmaceutical companies has so far been marginal.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150950

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel